PL3004077T3 - Nowe związki 3,4-dihydro-2H-izochinolin-1-onu i 2,3-dihydro-izoindol-1-onu - Google Patents

Nowe związki 3,4-dihydro-2H-izochinolin-1-onu i 2,3-dihydro-izoindol-1-onu

Info

Publication number
PL3004077T3
PL3004077T3 PL14728131T PL14728131T PL3004077T3 PL 3004077 T3 PL3004077 T3 PL 3004077T3 PL 14728131 T PL14728131 T PL 14728131T PL 14728131 T PL14728131 T PL 14728131T PL 3004077 T3 PL3004077 T3 PL 3004077T3
Authority
PL
Poland
Prior art keywords
dihydro
isoindol
isoquinoline
compounds
new
Prior art date
Application number
PL14728131T
Other languages
English (en)
Inventor
Johannes Aebi
Kurt Amrein
Wenming CHEN
Benoit Hornsperger
Bernd Kuhn
Yongfu Liu
Hans P. Maerki
Rainer E. Martin
Alexander V. Mayweg
Xuefei Tan
Lisha Wang
Mingwei Zhou
Original Assignee
F.Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F.Hoffmann-La Roche Ag filed Critical F.Hoffmann-La Roche Ag
Publication of PL3004077T3 publication Critical patent/PL3004077T3/pl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
PL14728131T 2013-05-27 2014-05-26 Nowe związki 3,4-dihydro-2H-izochinolin-1-onu i 2,3-dihydro-izoindol-1-onu PL3004077T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN2013076281 2013-05-27
EP14728131.5A EP3004077B1 (en) 2013-05-27 2014-05-26 New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
PCT/EP2014/060790 WO2014191338A1 (en) 2013-05-27 2014-05-26 New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds

Publications (1)

Publication Number Publication Date
PL3004077T3 true PL3004077T3 (pl) 2020-04-30

Family

ID=50884887

Family Applications (1)

Application Number Title Priority Date Filing Date
PL14728131T PL3004077T3 (pl) 2013-05-27 2014-05-26 Nowe związki 3,4-dihydro-2H-izochinolin-1-onu i 2,3-dihydro-izoindol-1-onu

Country Status (21)

Country Link
US (1) US9695151B2 (pl)
EP (1) EP3004077B1 (pl)
JP (2) JP6416229B2 (pl)
KR (1) KR102436885B1 (pl)
CN (1) CN105143204B (pl)
AR (1) AR096424A1 (pl)
BR (1) BR112015028871B1 (pl)
CA (1) CA2903180C (pl)
DK (1) DK3004077T3 (pl)
ES (1) ES2763338T3 (pl)
HR (1) HRP20192275T1 (pl)
HU (1) HUE046773T2 (pl)
LT (1) LT3004077T (pl)
MX (1) MX370389B (pl)
PL (1) PL3004077T3 (pl)
PT (1) PT3004077T (pl)
RS (1) RS59739B1 (pl)
RU (1) RU2695524C2 (pl)
SI (1) SI3004077T1 (pl)
TW (1) TWI651317B (pl)
WO (1) WO2014191338A1 (pl)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2014191338A1 (en) * 2013-05-27 2014-12-04 F. Hoffmann-La Roche Ag New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds
US11160751B2 (en) 2013-10-07 2021-11-02 Antares Pharma, Inc. Hematocrit modulation through needle assisted jet injection of testosterone
CR20170118A (es) * 2014-10-08 2017-07-10 Hoffmann La Roche Derivados espirodiamina como inhibidores de la aldosterona sintasa
EP3651762B1 (en) 2017-07-12 2024-07-03 Vanderbilt University Antagonists of the muscarinic acetylcholine receptor m4
JP7270989B2 (ja) 2017-10-20 2023-05-11 ヴァンダービルト ユニバーシティー ムスカリン性アセチルコリン受容体m4のアンタゴニスト
EP3732163A4 (en) 2017-12-20 2021-07-14 Vanderbilt University MUSCARIN M4 ACETYLCHOLIN RECEPTOR ANTAGONISTS
RU2717310C1 (ru) * 2019-06-04 2020-03-20 Общество с ограниченной ответственностью "Таргет Медикалс" Ингибиторы альдостеронсинтазы на основе производных 2-амино-4H-пиран-3-карбонитрила

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4710507A (en) * 1983-12-22 1987-12-01 Pfizer Inc. Quinolone inotropic agents
CN85100796A (zh) * 1985-04-01 1986-10-01 辉瑞公司 喹啉酮衍生物的制备方法
DE102008022221A1 (de) * 2008-05-06 2009-11-12 Universität des Saarlandes Inhibitoren der humanen Aldosteronsynthase CYP11B2
US8541404B2 (en) * 2009-11-09 2013-09-24 Elexopharm Gmbh Inhibitors of the human aldosterone synthase CYP11B2
EP2627648A1 (en) * 2010-09-16 2013-08-21 Novartis AG 17aHYDROXYLASE/C17,20-LYASE INHIBITORS
CA2832996C (en) * 2011-04-26 2019-05-07 Merck Sharp & Dohme Corp. Tricyclic triazole compounds and their use as aldosterone synthase inhibitors
HRP20192323T1 (hr) * 2011-09-15 2020-03-20 F. Hoffmann - La Roche Ag Novi derivati dihidrokinolin-2-ona
US9353081B2 (en) * 2011-09-23 2016-05-31 Hoffmann-La Roche Inc. Bicyclic dihydroquinoline-2-one derivatives
RU2693698C2 (ru) * 2013-05-27 2019-07-04 Ф. Хоффманн-Ля Рош Аг Новые соединения 3,4-дигидро-2н-изохинолин-1-она и 2,3-дигидроизоиндол-1-она
WO2014191338A1 (en) * 2013-05-27 2014-12-04 F. Hoffmann-La Roche Ag New 3,4-dihydro-2h-isoquinoline-1-one and 2,3-dihydro-isoindol-1-one compounds

Also Published As

Publication number Publication date
PT3004077T (pt) 2019-12-19
JP6670906B2 (ja) 2020-03-25
RU2015150287A (ru) 2017-06-28
KR20160012145A (ko) 2016-02-02
TWI651317B (zh) 2019-02-21
US9695151B2 (en) 2017-07-04
SI3004077T1 (sl) 2020-01-31
MX370389B (es) 2019-12-11
WO2014191338A1 (en) 2014-12-04
EP3004077A1 (en) 2016-04-13
CN105143204A (zh) 2015-12-09
JP2016520601A (ja) 2016-07-14
ES2763338T3 (es) 2020-05-28
RU2695524C2 (ru) 2019-07-23
KR102436885B1 (ko) 2022-08-26
RS59739B1 (sr) 2020-02-28
TW201533037A (zh) 2015-09-01
BR112015028871A2 (pt) 2017-07-25
EP3004077B1 (en) 2019-10-30
US20160075687A1 (en) 2016-03-17
DK3004077T3 (da) 2020-01-13
CA2903180C (en) 2022-03-15
HRP20192275T1 (hr) 2020-03-06
CN105143204B (zh) 2018-02-02
BR112015028871B1 (pt) 2022-02-01
HUE046773T2 (hu) 2020-03-30
MX2015015010A (es) 2016-03-09
HK1213564A1 (zh) 2016-07-08
CA2903180A1 (en) 2014-12-04
JP2019023212A (ja) 2019-02-14
JP6416229B2 (ja) 2018-10-31
AR096424A1 (es) 2015-12-30
LT3004077T (lt) 2020-01-27

Similar Documents

Publication Publication Date Title
IL240126A0 (en) (5, 3-Dimethylisoxazol-4-yl)indoline-2-ones that are converted at position 5
ZA201603549B (en) New pesticidal compounds and uses
ZA201600015B (en) Anti-fibrogenic compounds, methods and uses thereof
HUE046773T2 (hu) Új 3,4-dihidro-2H-izokinolin-1-on és 2,3-dihidro-izoindol-1-on vegyületek
GB201302863D0 (en) The Instaponytail
PT3004076T (pt) Novos compostos de 3,4-di-hidro-2h-isoquinolina-1-ona e de 2,3-di-hidro-isoindol-1-ona
GB201312513D0 (en) 2 4 1 Technology
ZA201508354B (en) Substituted5-(3,5-dimethylisoxazol-4-yl)indoline-2-ones
GB201322568D0 (en) Taggstar 1
GB201310407D0 (en) Plantladders 3
GB201310285D0 (en) Twist-Away 270
GB201301398D0 (en) Betterbidet new Jan 26th 2013
GB201320739D0 (en) The fold-a-way
GB201319475D0 (en) The wiperactive
GB201317585D0 (en) The dehydrometer
GB201316470D0 (en) The walkersize
GB201316056D0 (en) The hoddylock
GB201315586D0 (en) The adulation
GB201314047D0 (en) The Homeheater
GB201306173D0 (en) The Dehydrometer
GB201305912D0 (en) The barlaston wassail
GB201320379D0 (en) Concept 82
GB201313940D0 (en) Concept 75
GB201311530D0 (en) Concept 46
GB201311490D0 (en) Concept 53